A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Chondroitin Sulfate 800 mg Tablets Versus Placebo in Subjects With Pain Due to Knee Osteoarthritis and to Evaluate the Durability of the Effect and Safety of the Treatment

The goal of this phase III study is to evaluate the efficacy, safety, and tolerability of chondroitin sulfate 800 mg oral tablets versus placebo in the treatment of subjects with pain due to knee OA (osteoarthritis). The further aims of the study are to evaluate the durability of the treatment effect (up to week 36) and to gain further long-term safety and efficacy data (up to 48 weeks).
The primary outcome of interest will be the effect of chondroitin sulfate on pain in the index knee at week 24 compared to placebo.
The effect of chondroitin sulfate in the index knee functionality and the patient global impression of changes at 24 weeks compared to placebo are included as key-secondary endpoints. An additional key secondary endpoint will assess the durability of the effect on pain compared to placebo at week 36. Several additional secondary endpoints are included to further support the beneficial effect of the treatment and the improvements in patient's quality of life (i.e., Western Ontario and McMaster Universities Arthritis Index -WOMAC- subscales and total scores at each study visits, changes in patient's quality of life, use of rescue medication etc.) other than the safety of the product.

Start Date01 Dec 2023

Sponsor / Collaborator

IBSA Institut Biochimique SA

EUCTR2008-000871-19-FR

/ Not yet recruitingPhase 4

Comparative study of efficacy and safety of Structum® and Chondrosulf® in patients with symptomatic osteoarthritis of the knee.A Multicenter, Randomized, Double-Blind, Double Placebo-Controlled, Parallel Group Study

Start Date10 Apr 2008

Sponsor / Collaborator

Pierre Fabre Médicament SAS

NCT00604539

/ CompletedPhase 3

Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee

The purpose of this study is to determine the effect of a chondroitin sulphate conventional treatment on the degree of severity of synovitis, as measured by magnetic resonance in patients with knee OA with clinical synovitis.

Start Date01 Feb 2008

Sponsor / Collaborator

Bioibérica SA

100 Clinical Results associated with Chondroitin Sulfate Sodium

100 Translational Medicine associated with Chondroitin Sulfate Sodium

100 Patents (Medical) associated with Chondroitin Sulfate Sodium

Literatures (Medical) associated with Chondroitin Sulfate Sodium

13 May 2024·BIOMACROMOLECULES

Simultaneous Rosiglitazone Release and Low-Density Lipoprotein Removal by Chondroitin Sodium Sulfate/Cyclodextrin/Poly(acrylic acid) Composite Adsorbents for Atherosclerosis Therapy

Article

Author: Wei, Ran ; Xiao, Yujie ; Liu, Xianda ; Zhao, Changsheng ; Cheng, Shengjun ; Xu, Yinghui ; Zhao, Weifeng

Atherosclerosis (AS) is characterized by the accumulation of substantial low-density lipoprotein (LDL) and inflammatory response. Hemoperfusion is commonly employed for the selective removal of LDL from the body. However, conventional hemoperfusion merely focuses on LDL removal and does not address the symptom of plaque associated with AS. Based on the LDL binding properties of acrylated chondroitin sodium sulfate (CSA), acrylated beta-cyclodextrin (CD) and acrylic acid (AA), along with the anti-inflammatory property of rosiglitazone (R), the fabricated AA-CSA-CD-R microspheres could simultaneously release R and facilitate LDL removal for hemoperfusion. The AA and CSA offer electrostatic adsorption sites for LDL, while the CD provides hydrophobic adsorption sites for LDL and weak binding sites for R. According to the Sips model, the maximum static LDL adsorption capacity of AA-CSA-CD-R is determined to be 614.73 mg/g. In dynamic simulated perfusion experiments, AA-CSA-CD-R exhibits an initial cycle LDL adsorption capacity of 150.97 mg/g. The study suggests that the weakened inflammatory response favors plaque stabilization. The anti-inflammatory property of the microspheres is verified through an inflammation model, wherein the microsphere extracts are cocultured with mouse macrophages. Both qualitative analysis of iNOS\TNF-α and quantitative analysis of IL-6\TNF-α collectively demonstrate the remarkable anti-inflammatory effect of the microspheres. Therefore, the current study presents a novel blood purification treatment of eliminating pathogenic factors and introducing therapeutic factors to stabilize AS plaque.

01 Sep 2023·Carbohydrate polymers

Nano-elemental selenium particle developed via supramolecular self-assembly of chondroitin sulfate A and Na2SeO3 to repair cartilage lesions

Article

Author: Jia, Hongrui ; Zhang, Lan ; Han, Jing ; Wang, Linghang ; Qu, Chengjuan ; Qiao, Lichun ; Li, Yang ; Deng, Huan

Cartilage repair is a significant clinical issue due to its restricted ability to regenerate and self-heal after cartilage lesions or degenerative disease. Herein, a nano-elemental selenium particle (chondroitin sulfate A‑selenium nanoparticle, CSA-SeNP) is developed by the supramolecular self-assembly of Na₂SeO₃ and negatively charged chondroitin sulfate A (CSA) via electrostatic interactions or hydrogen bonds followed by in-situ reducing of l-ascorbic acid for cartilage lesions repair. The constructed micelle exhibits a hydrodynamic particle size of 171.50 ± 2.40 nm and an exceptionally high selenium loading capacity (9.05 ± 0.03 %) and can promote chondrocyte proliferation, increase cartilage thickness, and improve the ultrastructure of chondrocytes and organelles. It mainly enhances the sulfation modification of chondroitin sulfate by up-regulating the expression of chondroitin sulfate 4-O sulfotransferase-1, -2, -3, which in turn promotes the expression of aggrecan to repair articular and epiphyseal-plate cartilage lesions. The micelles combine the bio-activity of CSA with selenium nanoparticles (SeNPs), which are less toxic than Na₂SeO₃, and low doses of CSA-SeNP are even superior to inorganic selenium in repairing cartilage lesions in rats. Thus, the developed CSA-SeNP is anticipated to be a promising selenium supplementation preparation in clinical application to address the difficulty of healing cartilage lesions with outstanding repair effects.

01 Aug 2023·Journal of biomedical materials research. Part A

Scaffolds containing GAG‐mimetic cellulose sulfate promote TGF‐β interaction and MSC Chondrogenesis over native GAGs

Article

Author: Rameshwar, Pranela ; Sherman, Lauren ; Menezes, Roseline ; Arinzeh, Treena Livingston

Abstract:

Cartilage tissue engineering strategies seek to repair damaged tissue using approaches that include scaffolds containing components of the native extracellular matrix (ECM). Articular cartilage consists of glycosaminoglycans (GAGs) which are known to sequester growth factors. In order to more closely mimic the native ECM, this study evaluated the chondrogenic differentiation of mesenchymal stem cells (MSCs), a promising cell source for cartilage regeneration, on fibrous scaffolds that contained the GAG‐mimetic cellulose sulfate. The degree of sulfation was evaluated, examining partially sulfated cellulose (pSC) and fully sulfated cellulose (NaCS). Comparisons were made with scaffolds containing native GAGs (chondroitin sulfate A, chondroitin sulfate C and heparin). Transforming growth factor‐beta3 (TGF‐β3) sequestration, as measured by rate of association, was higher for sulfated cellulose‐containing scaffolds as compared to native GAGs. In addition, TGF‐β3 sequestration and retention over time was highest for NaCS‐containing scaffolds. Sulfated cellulose‐containing scaffolds loaded with TGF‐β3 showed enhanced chondrogenesis as indicated by a higher Collagen Type II:I ratio over native GAGs. NaCS‐containing scaffolds loaded with TGF‐β3 had the highest expression of chondrogenic markers and a reduction of hypertrophic markers in dynamic loading conditions, which more closely mimic in vivo conditions. Studies also demonstrated that TGF‐β3 mediated its effect through the Smad2/3 signaling pathway where the specificity of TGF‐β receptor (TGF‐ βRI)‐phosphorylated SMAD2/3 was verified with a receptor inhibitor. Therefore, studies demonstrate that scaffolds containing cellulose sulfate enhance TGF‐β3‐induced MSC chondrogenic differentiation and show promise for promoting cartilage tissue regeneration.

News (Medical) associated with Chondroitin Sulfate Sodium

03 Jan 2012

·www.biospace.com

Apricus Biosciences, Stellar Pharmaceuticals Inc. Sign MycoVa License Agreement in Canada

SAN DIEGO and MILTON, Ontario, Jan. 3, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI - News) ( ) and Stellar Pharmaceuticals Inc. ("Stellar Pharma") (OTCQB:SLXCF.PK - News) (OTCBB:SLXCF.PK - News) (Pink Sheets:SLXCF), a Canadian public company, announced today the signing of an exclusive license agreement. Under the agreement, Stellar Pharma has the exclusive right to sell Apricus Bio's MycoVa(TM) product for the treatment of onychomycosis (nail fungus) in Canada, following receipt of Canadian regulatory approval for such product. The exclusive license agreement provides for an upfront payment, regulatory approval milestone, sales achievement milestones and royalty payments during the term of the agreement. Onychomycosis is a chronic persistent fungal infection of the nail bed resulting in thickening and discoloration of the nail, which sometimes can be accompanied by serious pain and disability. According to the Merck Manual, the worldwide incidence rate of onychomycosis is approximately 10%. As described by Iorizzo and Piraccini (2007), the incidence has been increasing due to diabetes, immunosuppression and an aging population. While occurring in approximately 2.6% of children younger than 18 years, it occurs in as much as 90% of the elderly population (eMedicine.medscape.com). As of 2008, Thomson Reuters Pharma had stated that the worldwide market was approximately $2.8 billion in size and is expected to grow to approximately $2.9 billion by 2014. The advantage of Apricus Bio's MycoVa(TM) product is that it is easy to apply, and is therefore believed to improve patient compliance. MycoVa(TM) is applied to the infected nails, typically at bedtime, with minimal preparation, such as simply washing with soap and water. The formulation allows significant amounts of the drug to penetrate through the nail plate to the nail bed and surrounding area where fungus is located without significant systemic exposure. Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio commented, "We are very pleased with our exclusive license agreement with Stellar Pharma and we look forward to the future commercialization in the Canadian market of MycoVa(TM), our second major product utilizing our proprietary NexACT(R) technology. We are very impressed with the experience of Rob Harris and his team at Stellar Pharma, and we are very excited about this first potential launch of this important drug in that market. We also hope that our partnership with Stellar Pharma will produce additional collaborations among multiple NexACT(R) products in the future." Rob Harris, President and Chief Executive Officer of Stellar Pharma stated, "We are excited about this opportunity and are very pleased to be able to strengthen our dermatology portfolio in Canada. I would like to thank Bassam and his excellent team at Apricus Bio for providing us with this opportunity to launch MycoVa(TM) in the Canadian market. We will be assisting Apricus Bio in the filing of a New Drug Submission for MycoVa(TM) for onychomycosis and look forward to its commercial launch in Canada following Canadian regulatory approval." About MycoVa(TM) MycoVa(TM) combines an existing, approved drug for nail fungus, terbinafine, with the NexACT(R) technology that enhances the absorption of the drug through the skin. In January 2011, the Company announced that an additional analysis showed that MycoVa(TM) is as effective for the treatment of nail fungus as the current European standard of care for topical therapy, Loceryl(R) (an ointment made by Galderma). In June 2011, the Company announced that based on a reanalysis of its Phase III trials for its MycoVa(TM) product for treating onychomycosis (nail fungus), it is revisiting its regulatory strategy for the drug and will seek guidance from regulatory authorities in the U.S., Canada and Europe. A combined post-hoc analysis of two randomized, double-blind, vehicle controlled, multicenter, parallel group Phase III studies to assess the efficacy, safety and tolerability of MycoVa(TM) demonstrated statistically significant results in primary and secondary efficacy endpoints in favor of active treatment in patients who did not present with comorbid tinea pedis (athlete's foot), as these patients are considered at higher risk of reinfection. About Apricus Biosciences, Inc. Apricus Bio is a San Diego-based, revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes. Revenues and growth are driven from the sales of the Company's commercial products through its Apricus Pharmaceuticals USA, Inc. and NexMed (USA), Inc. subsidiaries and through out-licensing in certain territories of its product pipeline and NexACT(R) technology. Apricus Bio's current pipeline includes Vitaros(R), approved in Canada for the treatment of erectile dysfunction, Totect(R) the only drug approved in the US for the treatment of anthracycline extravasation, as well as compounds in development from pre-clinical through pre-registration currently focused on Sexual Dysfunction, Oncology, Dermatology, Autoimmune, Pain, Anti-Infectives, Diabetes and Consumer Healthcare. The Company also expects to develop and/or acquire and then bring to market additional pharmaceutical products in areas of care that will benefit patient needs worldwide. For further information on Apricus Bio, visit and for information on its subsidiary please visit You can also receive information at and About Stellar Pharmaceuticals Inc. Stellar Pharma and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market. Stellar Pharma currently competes in the dermatology market in Canada with its promotion of Soriatane(R)* (acitretin). Stellar Pharma also markets Bezalip(R)* SR (bezafibrate), NeoVisc(R) (1.0% sodium hyaluronate solution) and Uracyst(R) (sodium chondroitin sulfate solution 2%) in the Canadian market place and is awaiting regulatory approval for Cambia(R)** (diclofenac potassium for oral solution) in Canada. Additionally, NeoVisc(R) and Uracyst(R) are commercially available in 58 countries and are sold globally through various international partnerships. Stellar Pharma is currently in negotiations to license both NeoVisc(R) and Uracyst(R) in the US and other international markets. For further information on Stellar Pharma, visit and for information on its subsidiary please visit Apricus Bio's Forward-Looking Statement Safe Harbor Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, its ability to receive issued patents on its NexACT(R) technology and products, develop such patented technology into product candidates, have its Rx Division products and product candidates such as Vitaros(R) and MycoVa(TM) approved by relevant regulatory authorities and its Consumer Healthcare Division products either approved or cleared by relevant regulatory authorities or be in compliance with appropriate regulatory requirements, to successfully manufacture and commercialize such Rx Division products as Totect(R) for the treatment of anthracycline extravasation, Vitaros(R) for erectile dysfunction and MycoVa(TM) for onychomycosis in the U.S., Canada, and in other countries along with its Consumer Healthcare Division products and product candidates and to achieve its other development, commercialization and financial goals. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company. Stellar Pharmaceuticals' Forward Looking Statement This press release contains certain forward-looking statements about Stellar Pharma as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Stellar Pharma's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including general economic conditions, the ability of Stellar Pharma to successfully integrate operations, and the timing of expenditures and expansion opportunities, any of which could cause actual results to vary materially from current results or anticipated future results. See Stellar Pharma's reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties, that could cause actual results to differ materially from results referred to in forward-looking statements. Stellar Pharma assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time. *Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf **Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc. Contact: Apricus Biosciences, Inc.Edward Cox, V.P.Corporate Development & Investor Relations, Apricus Bio, Inc.(858) 848-4249ecox@apricusbio.comApricus Bio Investor RelationsPaula SchwartzRx Communications Group, LLC(917) 322-2216pschwartz@rxir.comStellar Pharmaceuticals Inc.Attention: Scott LangilleCFO(519) 434-1540scott.langille@stellarpharma.comAttention: Arnold TenneyChairman705-445-9505

CollaborateAcquisition

05 Aug 2009

·www.biospace.com

Stellar Pharmaceuticals Inc. Announces Record Second Quarter Revenues and Profitability for the First Half

LONDON, ONTARIO--(Marketwire - August 05, 2009) - Stellar Pharmaceuticals Inc. ("Stellar" or the "Company")(OTCBB: SLXCF) a Canadian pharmaceutical developer and marketer of high quality, cost effective products for select health care markets, today announced that its second quarter revenues increased by 65.8% to $1,074,300 compared to $647,900 for the same period last year and that the Company had a profit of $164,700 for the quarter compared to a loss of $68,000 in the second quarter of 2008. This is the third consecutive quarter that the Company has shown a profit. For the six month period ended June 30, 2009 Stellar's total revenues increased by 57.1% to $1,846,800 compared to $1,175,300 for the same period in 2008. Canadian sales for NeoVisc and Uracyst were up by 22.2% and 21.9% respectively for the period. International sales increased by 121.4% for this period as the Company's European partners continue to gain traction with both NeoVisc and Uracyst sales. The Company showed a profit of $189,900 for the first half of 2009 compared to a loss of $166,800 over the same period in 2008. Peter Riehl, Stellar's President and CEO, stated, "This is the strongest second quarter in the Company's history, with revenues up in all markets. We are very pleased to show profitability for the quarter and on a year-to-date basis, this currently puts the Company in a good position for strong operating results for the end of 2009. Besides these encouraging results, it has also been a very active quarter in other areas; Watson Pharmaceuticals received an IDE from the FDA and has now started a pilot clinical trial at a number of centers in the USA, the Company also launched its NeoVisc Single Dose (one injection) in mid June and we are very pleased with initial sales generated. In addition, the Company continues to actively search for new partners to out-license its products to around the world. It is very rewarding to see this growth and escalating business development activities, given the challenging economic times." About Stellar Pharmaceuticals Inc. Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings. STELLAR PHARMACEUTICALS INC. CONDENSED BALANCE SHEETS (Expressed in Canadian Dollars) As at As at June 30, 2009 December 31, 2008 --------------- ----------------- (Unaudited) (Audited) ASSETS CURRENT Cash and cash equivalents $ 1,882,040 $ 2,105,966 Accounts receivable, net of allowance $nil (2008 - $nil) 676,827 549,055 Inventories 651,296 364,551 Taxes recoverable 205,885 212,445 Loan receivable 18,369 18,369 Prepaids, deposits and sundry receivables 276,634 130,515 --------------- ----------------- 3,711,051 3,380,901 PROPERTY, PLANT AND EQUIPMENT 1,248,699 1,270,257 OTHER ASSETS 91,048 65,495 --------------- ----------------- $ 5,050,798 $ 4,716,653 --------------- ----------------- --------------- ----------------- LIABILITIES CURRENT Accounts payable $ 183,684 $ 173,812 Accrued liabilities 339,794 186,201 Deferred revenues 3,850 1,749 --------------- ----------------- 527,328 361,762 --------------- ----------------- CONTINGENCIES AND COMMITMENTS SHAREHOLDERS' EQUITY CAPITAL STOCK AUTHORIZED Unlimited Non-voting, convertible, redeemable, and retractable preferred shares with no par value Unlimited Common shares with no par value ISSUED 23,495,040 Common shares (2008 - 23,702,540) 8,188,486 8,261,403 Nil - Treasury shares (2008 - (147,500)) - (51,625) Additional paid-in capital for cancelled common shares 2,329 2,329 Additional paid-in capital options - outstanding 35,965 35,965 - expired 722,372 722,372 --------------- ----------------- 8,949,152 8,970,444 DEFICIT (4,425,682) (4,615,553) --------------- ----------------- 4,523,470 4,354,891 --------------- ----------------- $ 5,050,798 $ 4,716,653 --------------- ----------------- --------------- ----------------- STELLAR PHARMACEUTICALS INC. CONDENSED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS AND DEFICIT (Expressed in Canadian Dollars) (Unaudited) For the Three Month Period For the Six Month Period Ended June 30 Ended June 30 2009 2008 2009 2008 ------------ ------------ ------------ ------------- PRODUCT SALES $ 914,126 $ 645,535 $ 1,458,545 $ 974,991 COST OF PRODUCTS SOLD 333,082 148,937 488,034 260,332 ------------ ------------ ------------ ------------ MARGIN ON PRODUCTS SOLD 581,044 496,598 970,511 714,659 ROYALTY AND LICENSING REVENUES 160,168 2,400 388,265 200,356 ------------ ------------ ------------ ------------ GROSS PROFIT 741,212 498,998 1,358,776 915,015 ------------ ------------ ------------ ------------ EXPENSES Selling, general and administrative 562,941 551,893 1,140,996 1,042,885 Research and development 1,803 4,424 7,411 58,242 Amortization (non-manufacturing property, plant and equipment) 13,703 30,044 27,401 60,426 ------------ ------------ ------------ ------------ 578,447 586,361 1,175,808 1,130,269 ------------ ------------ ------------ ------------ INCOME (LOSS) FROM OPERATIONS 162,765 (87,363) 182,968 (215,254) INTEREST AND OTHER INCOME 1,929 19,349 6,903 48,423 ------------ ------------ ------------ ------------ NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD 164,694 (68,014) 189,871 (166,831) DEFICIT, beginning of period (4,590,376) (4,675,438) (4,615,553) (4,576,621) Effect of repurchase and cancellation of Common Shares - (2,933) - (2,933) DEFICIT, end of period $(4,425,682) $ (4,746,385) $ (4,425,682) $ (4,746,385) ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ EARNINGS (LOSS) PER SHARE $ 0.01 $ (0.00) $ 0.01 $ (0.01) ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING 23,495,040 23,755,759 23,816,387 23,788,919 ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ STELLAR PHARMACEUTICALS INC. CONDENSED INTERIM STATEMENTS OF CASH FLOWS (Expressed in Canadian Dollars) (Unaudited) For the Three Month Period For the Six Month Period Ended June 30 Ended June 30 2009 2008 2009 2008 ------------ ------------ ------------- ------------ CASH FLOWS USED IN OPERATING ACTIVITIES - Net income (loss) for the period $ 164,694 $ (68,014) $ 189,871 $ (166,831) Items not affecting cash Amortization 33,117 30,044 68,112 60,426 Unrealized foreign exchange (gain) loss 19,128 (7,912) 20,523 2,317 Issuance of equity instruments for services rendered - 7,538 - 13,125 Change in non-cash operating asset and liabilities (593,295) 2,788 (390,251) (109,397) ------------ ------------ ------------- ------------ CASH FLOWS USED IN OPERATING ACTIVITIES (376,356) (35,556) (111,745) (200,360) ------------ ------------ ------------- ------------ CASH FLOWS USED IN INVESTING ACTIVITIES - Additions to property, plant and equipment (43,938) (177,971) (44,135) (193,877) Increase to other assets (19,274) - (26,231) (6,063) ------------ ------------ ------------- ------------ CASH FLOWS USED IN INVESTING ACTIVITIES (63,212) (177,971) (70,366) (199,940) ------------ ------------ ------------- ------------ CASH FLOWS USED IN FINANCING ACTIVITIES - Repurchase of common shares for cash - (43,655) (21,292) (43,655) ------------ ------------ ------------- ------------ CASH FLOWS USED IN FINANCING ACTIVITIES - (43,655) (21,292) (43,655) ------------ ------------ ------------- ------------ EFFECT OF EXCHANGE RATES ON CASH HELD IN FOREIGN CURRENCY (19,127) 7,910 (20,523) (2,315) ------------ ------------ ------------- ------------ CHANGE IN CASH AND CASH EQUIVALENTS (458,695) (249,272) (223,926) (446,270) CASH AND CASH EQUIVALENTS, Beginning of period 2,340,735 3,014,128 2,105,966 3,211,126 ------------ ------------ ------------- ------------ CASH AND CASH EQUIVALENTS, End of period $ 1,882,040 $ 2,764,856 $ 1,882,040 $ 2,764,856 ------------ ------------ ------------- ------------ ------------ ------------ ------------- ------------ Contacts: Stellar Pharmaceuticals Inc. Peter Riehl President & CEO (800) 639-0643 or (519) 434-1540 Corpinfo@StellarPharma.com Stellar Pharmaceuticals Inc. Arnold Tenney (416) 587-3200

100 Deals associated with Chondroitin Sulfate Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D04078	Chondroitin Sulfate Sodium	M01AX25	DB09301

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Ophthalmologic surgical procedures	Japan	Alcon Japan Ltd.	20 Aug 2009
Corneal Ulcer	China	Jiangsu Puhua Kesheng Pharmaceutical Co Ltd	01 Jan 1982
Keratitis	China	Jiangsu Puhua Kesheng Pharmaceutical Co Ltd	01 Jan 1982
Hyperlipidemias	China	Tianjin Junan Biopharmaceutical Co Ltd.	01 Jan 1981
Corneal Injuries	Japan	Santen Pharmaceutical Co., Ltd.	31 Mar 1970
Arthralgia	Japan	Nippon Shinyaku Co., Ltd.	01 Nov 1963
Back Pain	Japan	Nippon Shinyaku Co., Ltd.	01 Nov 1963
Hearing Loss, Sensorineural	Japan	Nippon Shinyaku Co., Ltd.	01 Nov 1963
Neuralgia	Japan	Nippon Shinyaku Co., Ltd.	01 Nov 1963
Periarthritis	Japan	Nippon Shinyaku Co., Ltd.	01 Nov 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pain	Phase 3	-	IBSA Institut Biochimique SA	01 Dec 2023
Muscular Diseases	Phase 3	Canada	Bioibérica SA	01 Feb 2008
Osteoarthritis, Knee	Phase 3	Canada	Bioibérica SA	01 Feb 2008
Synovitis	Phase 3	Canada	Bioibérica SA	01 Feb 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


P080 (ECCO2014)	Not Applicable	Inflammatory Bowel Diseases C-reactive protein \| orosomucoid \| erythrocyte sedimentation rate ... View more	37	Chondroitin sulphate	htxrxxyban(zleudctgrb) = 43% of patients suffered adverse events, but only 5% were related to the drug khqmkpnbsh (wpmzdxewzd ) View more	Positive	01 Feb 2014
P080 (ECCO2014)	Not Applicable		37	Placebo		Positive	01 Feb 2014
P081 (ECCO2013)	Not Applicable	Inflammatory Bowel Diseases VEGFA \| VEGFC \| FGF2 ... View more	29	Condroitin sulphate (CS)	wsglngehsu(hipntetkca) = 30% of patients suffered adverse events, but only 6% were related to the drug bvtzgxlcfd (piokiacnvm )	Positive	01 Feb 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Chondroitin Sulfate Sodium

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation